AI assistant
Sending…
VYNE Therapeutics Inc. — Director's Dealing 2021
Feb 24, 2021
35290_dirs_2021-02-24_48d793a8-a7b5-4c82-8484-1d5952eba873.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-02-22
Reporting Person: Domzalski David (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-22 | Common Stock | A | 153750 | $0.00 | Acquired | 479833 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-22 | Stock Options | $8.33 | A | 358750 | Acquired | 2031-02-22 | Common Stock (358750) | Direct |
Footnotes
F1: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.
F2: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.